Induction treatments for acute promyelocytic leukemia: a network meta-analysis

Junjie Huang; Min Sun; Zitong Wang; Qiaoxia Zhang; Jin Lou; Yun Cai; Weihong Chen; Xin Du

doi:10.18632/oncotarget.12451

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Induction treatments for acute promyelocytic leukemia: a network meta-analysis

Junjie Huang, Min Sun, Zitong Wang, Qiaoxia Zhang, Jin Lou, Yun Cai, Weihong Chen and Xin Du _

PDF | HTML | How to cite

Oncotarget. 2016; 7:71974-71986. https://doi.org/10.18632/oncotarget.12451

Metrics: PDF 3003 views | HTML 2470 views | ?

Abstract

Junjie Huang1,*, Min Sun2,*, Zitong Wang3,*, Qiaoxia Zhang1, Jin Lou1, Yun Cai1, Weihong Chen1, Xin Du1

1Shenzhen Bone Marrow Transplantation Public Service Platform, Department of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University, Shenzhen 518000, China

2Department of General Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China

3The University of Sydney Medical School, Sydney, NSW 2006, Australia

*These authors have contributed equally to this work

Correspondence to:

Xin Du, email: [email protected]

Keywords: induction treatment, acute promyelocytic leukemia, network meta-analysis

Received: May 03, 2016 Accepted: September 28, 2016 Published: October 04, 2016

ABSTRACT

Background: 9 treatments for acute promyelocytic leukemia (APL) have been compared in many randomized controlled trials (RCT). The conclusions have been inconsistent and the purpose of this study is to conduct a network meta-analysis.

Results: Rankings of event-free survival are ATRA+RIF (81.2%), ATRA+ATO (69.6%), ATO (50.6%). Rankings of complete remission are ATRA+RIF (79.3%), ATRA+ATO (64.8%), RIF (60.3%), ATO (55.9%). Rankings of avoiding differentiation syndromes are CT (84.3%), ATO (80.3%), RIF (71.6%), ATRA+RIF (49%), ATRA+ATO (40.8%).

Methods: A total of 1,666 patients from 12 RCTs were enrolled. The frequentist method was used. Relative risks with 95% confidence intervals were calculated. We produced a network plot, a contribution plot, and a forest plot predictive intervals. The inconsistency factor, the surface under the cumulative ranking curve and the publication bias were evaluated.

Conclusions: ATRA+ATO is eligible to be the first-line treatment for APL. ATRA+RIF is a prospective alternative to the first-line treatment. RIF or ATO should be reconsidered as another option for de novo APL.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 12451

Publication Alerts

Research Papers:

Induction treatments for acute promyelocytic leukemia: a network meta-analysis

Abstract